X11L, a neuronal adaptor protein, associates with the cytoplasmic domain of APP and suppresses APP cellular metabolism. APP is the precursor of A␤, whose metabolism is strongly implicated in Alzheimer disease pathogenesis. To examine the roles of X11L function in APP metabolism, including the generation of A␤ in the brain, we produced X11L-deficient mutant mice on the C57BL/6 background. The mutant mice did not exhibit histopathological alterations or compensatory changes in the expression of other X11 family proteins, X11 and X11L2. The expression level and distribution of APP in the brain of mutant mice were also identical to those in wild-type mice. However, in the hippocampus, where substantial levels of X11L and APP are expressed, the mutant mice exhibited a significant increase in the level of the C-terminal fragments of APP produced by cleavage with ␤-secretase but not ␣-secretase. The levels of A␤ were increased in the hippocampus of aged mutant mice as compared with age-matched controls. These observations clearly indicate that X11L suppresses the amyloidogenic but not amyloidolytic processing of APP in regions of the brain such as the hippocampus, which express significant levels of X11L.
have identical functions, but the expression and localization of X11 and X11L differs among regions of the brain (17) . For example, in the hippocampus, X11L is expressed predominantly in excitatory pyramidal neurons, while X11 is strongly expressed in inhibitory neurons (18) . The hippocampus is a region susceptible to amyloid plaque formation, which contributes to dementia in AD (1) . Indeed, transgenic Tg2576 mice with the APP Swedish mutation which also overexpress X11 or X11L have decreased levels of cerebral A␤ and a reduction of A␤ plaques in the cortex and hippocampus (19, 20) , suggesting that X11 and X11L play an important role in the regulation of APP metabolism in vivo.
In contrast to these overexpression studies, RNAi silencing of X11 and X11L suppressed the generation of A␤40 from APP in neuroglioma cells (21) . Therefore, it is still unclear whether endogenous X11 and X11L have a crucial role in endogenous APP metabolism, including A␤ generation, and how X11 and X11L suppress the generation of A␤ in the brain. To address these issues, we produced X11L-deficient mice with gene-targeting technologies. X11L was originally isolated as an APPbinding protein and it has been more extensively analyzed than X11 (7, 15, 16, 22, 23) . We report here that X11L-deficient mice exhibit enhanced amyloidogenic but not amyloidolytic cleavage of APP in the hippocampus, indicating the importance of X11L function in APP metabolism in the brain and a possible role in AD pathogenesis.
EXPERIMENTAL PROCEDURES
Generation of X11L-deficient Mice-All experimental protocols were approved by the Animal Care and Use Committees of the Graduate School of Pharmaceutical Sciences, Hokkaido University and the University of Tokyo, and the RIKEN Brain Science Institute. A 14-kb genomic fragment containing exon 1 of the X11L gene from C57BL/6 mice was used to construct a targeting vector. A 1.4-kb XhoI-BsaHI fragment including the translation initiation site of X11L was replaced by the PGK-neo gene cassette flanked by loxP sites for a positive selection marker. A 1.1-kb MC1-DTA cassette, a negative selection marker, was added at the 3Ј-end of the targeting vector. After transfection of MS12 ES cells derived from C57BL/6 mice (24) and selection with G418, targeted clones were identified by Southern blot analysis. Chimeras were generated by injection of the targeted MS12 ES cells into Balb/c blastocysts and mated with C57BL/6 mice to obtain heterozygotes. The PGK-neo cassette flanked by loxP sites was excised by mating with CAG-Cre transgenic mice (25) . Mouse genotypes were determined by PCR using genomic DNA as a template and the primers L19: 5Ј-gtcgacggtatcgataagct-3Ј, L20: 5Ј-tgagtcctctctggaggtct-3Ј and L22: 5Ј-acatagcacacggtgcacat-3Ј (see Fig. 1a ). Fragments of 550 bp and 310 bp were amplified from wild-type and knock-out mutant alleles, respectively.
Antibodies-The polyclonal anti-APP cytoplasmic domain antibody G369 was a gift from Dr. S. Gandy and has been described previously (26) . Monoclonal antibodies recognizing X11/mint1, X11L/mint2, X11L2/mint3, cis-Golgi matrix protein GM130 (BD Biosciences), APP extracellular domain (22C11) (Chemicon), microtubule-associated protein 2 (MAP2) (Chemicon and Sigma), protein-disulfide isomerase (PDI) (1D3, Stressgen Biotechnologies), sAPP␣ (2B3, IBL), glial fibrillary acidic protein (GFAP) (PROGEN), and synaptophysin (DAKO), and polyclonal antibodies recognizing phosphoThr 668 -APP (Cell Signaling), sAPP␤ (IBL), and anti-BACE (Calbiochem) were purchased from the indicated commercial sources. Horseradish peroxidase-conjugated anti-␤-tubulin was purchased from Santa Cruz Biotechnology. The anti-A␤ antibodies BNT77, BC05, and BA27 were supplied by Takeda Pharmaceutical Company Ltd. (Osaka, Japan).
Immunohistochemistry-Mice were deeply anesthetized with tribromoethanol (avertin) and transcardially perfused with physiological saline and then 4% (w/v) paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4, at 4°C for 20 min. The brains were excised, postfixed with the same fixative at 4°C overnight, and equilibrated in 30% (w/v) sucrose in PBS as a cryoprotectant. The brains were embedded in OCT compound (Sakura Finetech), and frozen coronal sections (20 m) were prepared. Immunohistochemical staining was performed using the ABC method (Vector Laboratories). Free-floating sections were incubated with 0.1% (v/v) Triton X-100 in PBS followed by incubation with 0.3% (v/v) hydrogen peroxide in PBS to quench endogenous peroxidase activity. The sections were then blocked with 5% (v/v) horse or goat serum in PBS. After overnight incubation at 4°C with primary antibodies, the sections were further incubated with horse anti-mouse IgG or goat antirabbit IgG antibodies conjugated to biotin (Vector Laboratories), followed by the ABC complex. Peroxidase activity was revealed using diaminobenzidine as the chromogen.
Preparation of Mouse Brain Lysate and a Crude Membrane Fraction-Total brain and hippocampal tissues were dissected on ice immediately after cervical dislocation. Tissue samples were homogenized in a 10-fold volume of radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris-HCl, pH 8.0, containing 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Nonidet P-40, and 150 mM NaCl) containing a complete protease inhibitor mixture (Roche Applied Science) with pepstatin A (5 g/ml), and centrifuged at 14,200 ϫ g for 20 min at 4°C. The supernatant (crude lysate) was used for Western blot analysis. In other experiments, the tissues were homogenized on ice in a 10-fold volume of buffer A (5 mM HEPES. pH 7.4 containing 0.32 M sucrose) containing a complete protease inhibitor mixture with pepstatin A (5 g/ml) at 900 rpm by 12 strokes of a Teflon homogenizer. Samples were centrifuged at 1,400 ϫ g for 5 min at 4°C and the resulting postnuclear supernatants were further centrifuged at 14,200 ϫ g for 20 min at 4°C. The pellets (crude membrane fraction) were used for Western blot analysis.
Western Blot Analysis-The indicated amounts of protein lysates were separated by SDS-PAGE (8% (w/v) polyacrylamide Tris-glycine gels for X11, X11L, X11L2, APP and a large extracellular N-terminal domain truncated at the ␣-site (sAPP␣) and/or the ␤-site (sAPP␤), and 16% (w/v) polyacrylamide TrisTricine gels for APP CTFs, or 7.5% (w/v) polyacrylamide Trisglycine gels for subcellular fractions). The separated proteins were transferred onto polyvinylidene difluoride membranes and probed with primary antibodies. The ECL-advance detection system (GE Healthcare) or Western blotting Luminol Reagent (Santa Cruz Biotechnology) was used for detection of immunoreactive proteins. Band densities were quantified using the Scion Image program (Scion Corp.) and normalized to ␤-tubulin or MAP2 as an internal control. Student's two-tailed t test analysis was performed to determine statistical significance. p values less than 0.05 were considered statistically significant.
Detection of Hippocampus sAPP-Hippocampal tissues were dissected as described above, homogenized in a 2-fold volume of Tris-buffered saline (TBS, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl) containing 5 g/ml chymostatin and 5 g/ml leupeptin, and centrifuged at 200,000 ϫ g for 20 min at 4°C. The resulting supernatant included almost all the sAPP and was analyzed by Western blotting with anti-pan sAPP, anti-sAPP␣, and antisAPP␤ antibodies.
Quantification of A␤40 and A␤42 in the Hippocampus of X11L-deficient Mice-A␤ was measured by previously described methods (27) with some modifications. Hippocampi dissected from 15ϳ16-month-old mice (tissues from three mice were combined in each assay) were homogenized in a 6-fold volume of TBS (pH 7.6), containing a complete protease inhibitor mixture with pepstatin A (0.7 g/ml). The homogenates were transferred to a polyallomer tube (Beckman 357448) and centrifuged (200,000 ϫ g) for 20 min at 4°C with a TLA 100.4 rotor. The supernatant was collected and 9.1 l of 6 M guanidine chloride in TBS was added to 100 l of supernatant and used for quantification of soluble A␤. The pellet was washed in TBS with centrifugation at 200,000 ϫ g for 5 min, and an equal volume of 6 M guanidine chloride in TBS was added to the washed pellet. The pellet was sonicated for 30 s and allowed to stand for 60 min at room temperature. Then, the sample was centrifuged at 200,000 ϫ g for 20 min, and the supernatant was recovered. The sample was diluted with a 12-fold volume of ELISA blocking buffer (PBS containing 25% (w/v) Block Ace (Dainippon Pharmaceuticals), 0.05% (w/v) NaN 3 and a complete protease inhibitor mixture) and centrifuged at 14,000 ϫ g for 5 min. The resulting supernatant was used for quantification of insoluble A␤.
A 96-well ELISA plate was coated with BNT77 (10 g/ml in 0.1 M carbonate buffer pH 9.5) at 4°C overnight. The wells were washed with PBS and buffer EC (0.02 M phosphate buffer, pH 7.0, containing 0.4 M NaCl, 2 mM EDTA, 10% (w/v) Block Ace, 0.2% (w/v) bovine serum albumin, 0.05% (w/v) NaN 3 , and 0.075% (w/v) CHAPS was added to the wells. Aliquots (200 l) of samples and synthetic A␤40 or A␤42 peptides as calibration standards were poured into the wells, and the plates were incubated at 4°C overnight. The wells were washed with PBS four times, and the horseradish peroxidase-conjugated BA27 antibody specific for A␤40 or the horseradish peroxidase-conjugated BC05 antibody specific for A␤42 was added, and the plates were incubated at 4°C overnight. The plates were washed with PBS and PBS containing 0.05% (v/v) Tween 20. An aliquot (100 l) of substrate solution (TMB microwell peroxidase substrate system; Kirkegaard & Perry Lab. Inc.) was added to the wells, and the plates were incubated at room temperature for 5-20 min. Stop solution (100 l; 1 M H 3 PO 4 ) was added, and the absorbance at 450 nm was measured with a microplate reader.
RESULTS

Generation of an X11L-deficient Mutant Mouse
Line-Mutant mice were generated by a standard gene knock-out method using an ES cell line derived from mice with the C57BL/6 background. We constructed a targeting vector that lacked the translation initiation site (Fig. 1a) . Mutant mice carrying an allele without the PGK-neo gene cassette were backcrossed to C57BL/6 mice several times, and heterozygous mice were then intercrossed to produce homozygotes. Thus, the mutant lines produced in this study were coisogenic with the C57BL/6 strain. The mutation was confirmed by Southern blot (data not shown) and PCR (Fig. 1b) analyses. We also confirmed the protein deficit by Western blot analysis using an anti-X11L antibody (Fig. 1c) . There was no X11L in the brain of homozygous (Ϫ/Ϫ) mutant mice, while approximately half the wild-type Schematic of the targeting construct (i), a partial structure of the X11L allele, including the codon with the first methionine (ATG) (ii), the resulting targeted allele (iii), and the targeted allele after Cre-recombination (iv) are shown. The filled box denotes the coding sequence of exon 1. External and internal probes for Southern blot analysis for screening targeted ES clones are indicated. PCR primers (L19, L20, L22) for genotyping of mice are indicated with arrowheads. PGK-neo, neomycin resistance gene driven by a phosphoglycerate kinase promoter; MC1-DTA, diphtheria toxin A fragment gene driven by an MC1 promoter (42) . b, PCR products specific to the wild-type allele (ϩ/ϩ) generated with the L22 and L20 primers (550 bp, arrow 1) and to the targeted allele (ϩ/Ϫ and Ϫ/Ϫ) generated with the L19 and L20 primers (310 bp, arrow 2) were analyzed by agarose gel electrophoresis. c, Western blot analysis of X11L. Whole brain lysates (2.5 g of protein in RIPA lysis buffer) of wild type (ϩ/ϩ), heterozygous mutant (ϩ/Ϫ), and homozygous mutant (Ϫ/Ϫ) mice were subjected to Western blot analysis with an anti-X11L antibody. Arrows indicate X11L proteins. d, immunostaining of hippocampal coronal sections of wild type (ϩ/ϩ) and homozygous mutant (Ϫ/Ϫ) mice (2ϳ3 months) with the anti-X11L antibody. e, Nissl-stained coronal section of the brain of wildtype (ϩ/ϩ) and homozygous mutant (Ϫ/Ϫ) mice.
(ϩ/ϩ) level was observed in the brain of heterozygotes (ϩ/Ϫ). Another X11L antibody, UT30, which recognizes the C-terminal region of X11L (7), also did not detect X11L in the brain of homozygous mutant mice (data not shown). These results indicate that homozygous mutant mice express neither full-length X11L nor truncated X11L derivatives. This was further confirmed by immunostaining of the hippocampal region, which expresses substantial levels of X11L in wild-type mice (ϩ/ϩ in Fig. 1d ). For homozygous mutant mice, immunostaining was not observed in any brain region (data not shown) including the hippocampus (Ϫ/Ϫ in Fig. 1d ), while Nissl staining did not reveal any cytoarchitectural abnormalities in the hippocampal region of the brain (Fig. 1e) . Other brain regions were also histochemically normal (data not shown). The homozygous mutant mice had no overt behavioral abnormalities and bred normally.
Expression and Distribution of X11, X11L2, and APP in the Hippocampus of X11L-deficient Mice-We focused our analysis of X11L-deficient mice on the hippocampus, because the expression of X11L protein in this region is high and its localization differs from that of X11 (17) . We examined the levels of X11 and X11L2 in the hippocampus (Fig. 2) , and the expression and distribution of APP and other neural proteins (Figs. 2 and 3). We first tested whether there are changes in the expression of X11 and X11L2 in the hippocampal region of X11L-deficient mice. In both younger (3 months) and older (24 months) adult mice, no remarkable changes in X11 or X11L2 protein expression were observed (X11, p ϭ 0.33 (3 months) and p ϭ 0.33 (24 months); X11L2, p ϭ 0.94 (3 months) and p ϭ 0.52 (24 months)). We also did not detect significant changes in these proteins in the whole brain of aged mice (data not shown), indicating that there was no compensatory increase in the expression of X11 and X11L2 because of the absence of X11L in the brain of mutant mice. Expression of full-length APP composed of mature (mAPP, N-and O-glycosylated form) and immature (imAPP, N-glycosylated form) forms (28) was also quantitatively similar in young adult and aged mice (3 months, p ϭ 0.43; 24 months, p ϭ 0.81) (Fig. 2) .
Protein localization in the hippocampal region of aged (16ϳ17 months) wild type (ϩ/ϩ) and homozygous mutant (Ϫ/Ϫ) mice was compared by immunostaining (Fig. 3) . Immunostaining of hippocampal CA1 sections with antibodies to APP, GFAP, MAP2, and synaptophysin did not show remarkable differences between wild-type and mutant mice. APP was strongly expressed in the pyramidal neurons of the CA1 region, as was X11L (Fig. 1d) , and its cellular localization was identical in wild-type and mutant mice; gliosis was not observed in wildtype or mutant mice. Moreover, no differences were detected in MAP2 and synaptophysin expression or in Nissl staining in wild-type and mutant mice, suggesting that there are no histopathological neuronal abnormalities, such as synaptic loss or dendritic atrophy, in the hippocampus of the X11L-deficient mouse.
Deficit of X11L Increases the Level of ␤-Cleavage Products of APP in the Hippocampus-To examine the role of X11L in endogenous APP processing in vivo, we first analyzed the brain content of C-terminal fragments of APP produced by cleavage with ␣-and ␤-secretases. Cleavage by ␣-secretase generates CTF␣, which is composed of the C-terminal 83 amino acids (C83), and ␤-secretase generates two CTF␤ fragments, C99 and C89 (29) . Because CTFs are phosphorylated at Thr 668 , we treated CTFs with lambda protein phosphatase (PPase) to identify CTF species (Fig. 4a) , as described (30) . In the mouse brain, five CTF species can be detected by Western blot analysis: phosphorylated C99 (pC99), C99, phosphorylated C89 (pC89), a mixture of C89, and phosphorylated C83 (pC83), and C83 (31) . Treatment of immunoprecipitates containing these CTFs with PPase resulted in the appearance of three discrete bands corresponding to C99, C89, and C83 on Western blots (Fig. 4a) . CTFs in the hippocampus and whole brain of wild-type and mutant mice were analyzed by Western blotting (Fig. 4b) , and the total levels of CTFs were normalized to ␤-tubulin, which is detected in membrane or cytoplasmic fractions at a constant level (32) (Fig. 4c) . The relative amounts of ␤-tubulin, synapsin, and NMDA receptor subunit 1 (NR1) in crude membrane fractions were comparable between wild-type and mutant mice (supplemental Fig. S1 ). In the hippocampus of middle-aged (12ϳ13 months) and old (28 months) mutant mice, total CTFs increased significantly when compared with those in the hippocampus of wild-type mice (12ϳ13 months, p ϭ 0.004; 28 months, p ϭ 0.003). The total amount of CTFs tended to increase in the hippocampus of young adult (4ϳ5 months) mutant mice, although the difference between genotypes was not statistically significant (p ϭ 0.07).
There were no marked differences in the level of total CTFs in the whole brain of wild-type and mutant mice (p ϭ 0.46), even for 28-month-old mice. The level of CTF␤ (a mixture of FIGURE 3. Expression and distribution of proteins in the hippocampal CA1 region of X11L-deficient mice. Coronal sections of the hippocampal CA1 region of wild type (left panels, ϩ/ϩ) and X11L homozygous mutant (right panels, Ϫ/Ϫ) mice (16ϳ17 months) were immunostained for APP (panels a and b), GFAP (an astrocytic marker, panels c and d), MAP2 (a neuronal dendritic marker, panels e and f), and synaptophysin (a presynaptic marker, panels g and h). Sections were also Nissl-stained (panels i and j). S.o., stratum oriens; Py, pyramidal neuron; Rad, stratum radiatum. The scale bar is 100 m. FIGURE 4. The hippocampus of X11L-deficient mice exhibits an increase in the level of amyloidogenic C-terminal fragments of APP. a, identification of APP C-terminal fragments cleaved by ␣-and ␤-secretases. APP C-terminal fragments (CTFs) in brain RIPA lysates (300 g of protein) of wild-type mice were isolated by immunoprecipitation with the anti-APP cytoplasmic G369 antibody, and the immunoprecipitates were treated with (ϩ) or without (Ϫ) PPase. CTFs were identified as described (30) . C99 and C89 are products cleaved by ␤-secretase (28). C83 is a product cleaved by ␣-secretase. The proteins pC99, pC89, and pC83 are C99, C89, and C83 phosphorylated at Thr 668 (30) . b, CTFs in the hippocampus and whole brain of younger (4ϳ5 months (M)) and older (12ϳ13 and 28 months (M)) adult wild type (ϩ/ϩ) and X11L homozygous mutant (Ϫ/Ϫ) mice. Crude membrane fractions (40 g of protein) of hippocampus and whole brain were subjected to by Western blot analysis with G369 and anti-␤-tubulin antibodies. c, band densities of CTFs for wild type (open columns) and X11L-deficient (filled columns) mice of each age were standardized to the density of ␤-tubulin, which was normalized to one for wild-type mice. d, amounts of CTF␤ (a mixture of C99 plus pC99) were quantified as described in c. The error bars indicate S.E. (n ϭ 4). Statistical significance is indicated with asterisks (*, p Ͻ 0.05; **, p Ͻ 0.01).
C99 and pC99) in the hippocampus increased 1.5ϳ2-fold in mutant mice of all ages examined (4ϳ5 months, p ϭ 0.008; 12ϳ13 months, p ϭ 0.005; 28 months, p ϭ 0.02), while there was no significant increase in the whole brain of mutant mice (28 months, p ϭ 0.10) (Fig. 4d) .
Because C89 and pC83 could not be separated by electrophoresis, the crude membrane fractions containing CTFs recovered from the hippocampi of eight wild-type and eight mutant mice (17ϳ18 months, the respective hippocampi of two mice were combined) were dephosphorylated to separate CTF␣ (C83) from CTF␤ (C89), subjected to Western blot analysis, and CTFs were quantified (Fig. 5) . In mutant mice, both CTF␤ C99 and C89 increased significantly, ϳ1.5-fold, but the hippocampal levels of CTF␣ C83 did not change when compared with levels in wild-type mice (C99, p ϭ 0.001; C89, p ϭ 0.017; C83, p ϭ 0.89).
To explore the cause of increased generation of CTF␤ in the brains of mutant mice, we examined the subcellular distribution of APP and BACE with iodixanol fractionation of a postnuclear brain lysate (supplemental Fig. S2 ). As previously reported (15) , mAPP was largely recovered in Golgi (concentrated in fractions 8 -11 as indicated by the GM130 Golgi marker protein) and post-Golgi secretory pathway membranes, as well as the plasma membrane fraction (prior to fraction 8), which also contains BACE (33, 34) . In brain of mutant mouse, the BACE and APP distributions overlapped more than in wildtype brain. This may facilitate ␤-site cleavage of APP in the mutant mice.
We also examined phosphorylation levels of CTFs in wildtype and mutant mice, because CTFs contain the major APP phosphorylation site Thr 668 (numbering for APP695 isoform) in neurons (28) . The specific activity of the phosphorylations (pCTFs/CTFs and pC99/C99) did not change significantly in the hippocampus of mutant mice (supplemental Fig. S3 ). These data are consistent with our observation that the phosphorylation level of APP did not differ noticeably between aged wildtype and mutant mice. 4 Because the deficiency in X11L enhanced the ␤-cleavage of APP and resulted in an increase in CTF␤, the mutant mice should also exhibit an increase in sAPP␤ level. The sAPP level in the hippocampus was examined by Western blotting with anti-pan sAPP, anti-sAPP␣, and anti-sAPP␤ antibodies, and normalized to MAP2 levels (Fig. 6) . Interestingly, the total amount of sAPP significantly decreased in the hippocampus of mutant mice. A similar decrease was observed in sAPP␣, but not sAPP␤ (Total sAPP, p ϭ 0.03; sAPP␣, p ϭ 0.02; sAPP␤, p ϭ 0.32). Although the decrease in sAPP␤ was not significant when compared with the marked decrease of sAPP and sAPP␣, it is difficult to conclude whether the increased ␤-site cleavage of APP compensated for the sAPP␤ level in the hippocampus in vivo. Therefore, we quantified the A␤ level in the hippocampus.
The increase in CTF␤ in the X11L-deficient hippocampus implies an increased generation of A␤. Therefore, we assayed the level of A␤ in the hippocampus of aged (15ϳ16 months) mice (Fig. 7) . A␤40 and A␤42 were largely recovered in the TBS-insoluble fraction, as previously described (27) . The levels of A␤40 and A␤42 in the TBS-insoluble fraction significantly increased, ϳ1.5-fold and ϳ2-fold, respectively, in X11L-deficient mice compared with wild-type mice (p ϭ 0.002 for A␤40 and p ϭ 0.048 for A␤42). These results clearly indicate that the amyloidogenic cleavages mediated by ␤-secretase increase in the hippocampus of X11L-deficient mice, resulting in enhanced generation of A␤.
DISCUSSION
X11L was originally isolated as an APP-binding protein, and its role in APP metabolism has been extensively analyzed in cells (7, 15, 22, 35) . The association of X11 or X11L2 with APP also suppresses APP metabolism and decreases the production of A␤ (6, 8) . These in vitro results indicate that X11 family proteins regulate APP metabolism and their deregulation may 4 T. Suzuki, unpublished observation. coincide with aberrant A␤ generation in brain tissues. In particular, X11 and X11L are neuron-specific proteins and are candidates as therapeutic targets for AD drug development (36) . However, knock-down of X11 and X11L with RNAi in cultured cells produced complex effects on APP metabolism. In X11-knock down cells, CTF␣ and CTF␤ increased but A␤ decreased, whereas both CTF␣ and CTF␤ were unchanged but A␤ decreased in X11L-knock-down cells (21) . These results are not consistent with the changes in APP metabolism with overexpression of X11 and X11L (6, 7, 15, 19, 20) . Therefore, it is important to explore APP metabolism in the brains of X11-and/or X11L-deficient mice. In particular, it is crucially important to know whether endogenous X11 and X11L regulate APP metabolism in the brain, and if so, how they control the generation of A␤. Analyses of X11-or X11L-deficient mice are relevant for resolving these issues. X11-deficient mice have been produced by different groups (14, 37) . Although X11-deficient mice have shown an abnormal synaptic transmission in the inhibitory neurons of the hippocampus and a reduction in the release of dopamine in the substantia nigra, the metabolism of APP and the generation of A␤ have not been analyzed. We have produced X11L-deficient mice, which do not show obvious abnormalities with respect to behavior or brain structure. We used this X11L-deficient mouse to elucidate the in vivo function of X11L in APP metabolism.
Both X11 and X11L are widely distributed in brain tissues, but their localization patterns are different (17, 18) . X11L is ubiquitously expressed in the brain, with particularly notable levels in the hippocampus, along with a comparable level of expression of APP. X11L is located predominantly in excitatory pyramidal neurons, while X11 is more strongly expressed in inhibitory neurons. Pyramidal neurons in the hippocampus are crucial for learning and memory, and impairment of hippocampal functions in AD causes dementia. Therefore, we focused our analysis of APP metabolism on the hippocampus of X11L-deficient mice. Our study has revealed alterations in APP metabolism in the hippocampus of X11L-deficient mice. The lack of significant differences in the whole brain samples might reflect the redundant role of X11 or X11L2 in other brain regions.
We detected a significant increase in CTF␤ in the hippocampus of mutant mice of all ages examined, even though there were not notable differences in the amount of total APP. These data suggest that a deficit in X11L affects the amyloidogenic metabolism of APP. Interestingly, the amyloidolytic processing that generates C83 did not decrease in the hippocampus of X11L-deficient mice, which suggests that the increased level of CTF␤ in these mice results from a net increase of APP cleavage at the ␤-site. Suppression of APP metabolism by X11L may not redirect APP into the amyloidolytic pathway from the amyloidogenic pathway, because the levels of C83 CTF␣ did not decrease in concert with the increase in CTF␤. Previous studies using cultured cells have suggested that X11L suppresses both ␣-and ␤-site cleavages (15) . Unlike the in vitro results, the present in vivo observations indicate that X11L selectively affects ␤-site cleavage of APP. One possibility is that X11L suppresses physical contact between APP and BACE via X11L binding to APP without impairing major APP processing at the ␣-site in the brain. Alternatively, X11L may alter the intracellular distribution of APP and/or BACE. In fact, more BACE co-distributed with APP in the Golgi and post-Golgi secretory pathway membranes in the brains of X11L-deficient mice compared with BACE and APP co-distribution in the wild-type brain. Although the overlap in BACE and APP distribution in brain lysate fractions may correlate with the increase in cleavage of APP at the ␤-site in mutant mice, further detailed analysis to determine the mechanism by which X11L suppresses ␤-cleavage of APP is an issue to be resolved in future studies.
If these in vivo results more accurately reflect the corresponding phenomena in the human brain than do the in vitro results, our present observations suggest that X11L may serves as a suitable target of drug therapy for ␤-site cleavage.
The increased level of CTF␤ in the hippocampus of X11L-deficient mice was expected to lead to a corresponding increase in sAPP␤, but we did not detect an increase in sAPP␤ in the hippocampus because the total sAPP level decreased in the mutant mouse hippocampus. The decrease in sAPP␤ was not significant when compared with that of sAPP␣. Because several reports suggest that X11 and X11L function in exocytosis (38, 39) , the release and/or proteolytic degradation of sAPP may also be affected in the X11L-deficient mice. The increased level of CTF␤ led to an increase in the generation of A␤ in the hippocampus of X11L-deficient mice. The increase in CTF␤ (1.5ϳ2-fold) in the X11L-deficient hippocampus correlated with the levels of A␤40 and A␤42. The initial cleavage of APP by ␣-or ␤-secretase is thought to be a rate-determining step in A␤ generation. Once APP is subjected to a first cleavage, the generated CTFs are believed to be quickly cleaved by ␥-secretase. A previous study using cells expressing C99 CTF␤ indicated that X11L suppresses the ␥-cleavage of C99 by blocking access to presenilin (15) . Thus, it is also possible that the deficit in X11L may facilitate the ␥-cleavage of CTF␤ to generate A␤ in the brain, although an in vitro study with RNAi silencing of X11L would appear to exclude this possibility (21) . We have examined whether amyloid deposits are observed in the brain of aged mutant mice by immunostaining with the anti-A␤ antibody 4G8. However, we did not detect amyloid plaques in sections of X11L-deficient mouse brains, 4 perhaps because of the poor fibril-forming ability of mouse A␤ (40) . Crossbreeding of X11L-deficient mice with transgenic mice bearing human APP may generate a novel animal model with a better AD pathology. The present results clearly indicate that X11L serves to suppress the amyloidogenic metabolism of APP and decreases A␤ generation in the brain.
Our conclusions are largely consistent with previous observations obtained from in vitro studies with cultured cells (7, 15, 36, 41) and the X11L-overexpressing Tg mouse (20) . Although it remains to be determined whether X11L suffers qualitative changes in the aged or AD brain, functional deficiency or aberration of X11L associated with aging may cause the sporadic type of late onset AD.
